Analysts Set Evommune, Inc. (NYSE:EVMN) PT at $49.67

Evommune, Inc. (NYSE:EVMN) has been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $49.6667.

EVMN has been the topic of a number of recent analyst reports. William Blair initiated coverage on Evommune in a report on Monday, December 1st. They set an “outperform” rating on the stock. Wall Street Zen upgraded Evommune from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. Weiss Ratings started coverage on Evommune in a research note on Tuesday, February 3rd. They set a “sell (e)” rating on the stock. The Goldman Sachs Group upgraded Evommune to a “buy” rating in a research note on Wednesday, January 7th. Finally, Evercore reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Evommune in a report on Tuesday, February 10th.

Evommune Price Performance

Shares of EVMN stock opened at $21.86 on Wednesday. The business has a fifty day simple moving average of $22.66. The stock has a market capitalization of $787.22 million and a price-to-earnings ratio of -2.71. Evommune has a 52 week low of $13.89 and a 52 week high of $33.20.

Evommune (NYSE:EVMN) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.61).

Hedge Funds Weigh In On Evommune

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. bought a new stake in Evommune during the fourth quarter worth approximately $1,056,000. Burkehill Global Management LP bought a new position in Evommune during the fourth quarter valued at $856,000. Tudor Investment Corp ET AL purchased a new position in shares of Evommune during the 4th quarter worth about $547,000. State Street Corp bought a new position in Evommune during the 4th quarter valued at about $539,000. Finally, Oxford Asset Management LLP purchased a new stake in Evommune in the 4th quarter worth about $335,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.